礼来的销售额中值预计较2024年增长约32%，增长主要由礼来新药如Zepbound、Mounjaro、Jaypirca、Ebglyss、Omvoh以及Kisunla推动；现有礼来药物的新适应症获批；Mounjaro将在更多全球市场推出；以及像imlunestrant这种用于治疗转移性乳腺癌的新药潜在上市。公司还继续在增大生产能力方面进行重大投资，并预计到2025年上半年，销售型促肠蠕动药物的产量将至少达到2024年上半年的1.6倍。
以上内容来自Benzinga Earnings专栏，原文如下：
The midpoint represents approximately 32% growth compared to 2024, driven by new Lilly medicines such as Zepbound, Mounjaro, Jaypirca, Ebglyss, Omvoh and Kisunla; approvals of new indications for existing Lilly medicines; launches of Mounjaro in additional worldwide markets; and potential launches of new medicines such as imlunestrant for metastatic breast cancer. The company continues to invest heavily in increasing manufacturing capacity and estimates producing at least 1.6 times the amount of salable incretin doses in the first half of 2025, compared to the first half of 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.